Meeting
2012 ASCO Annual Meeting
Neoadjuvant accelerated MVAC (AMVAC) in patients with muscle invasive bladder cancer: Results of a multicenter phase II study.
Authors
Elizabeth R. Plimack
Fox Chase Cancer Center, Philadelphia, PA
Elizabeth R. Plimack , Jean H. Hoffman-Censits , Rosalia Viterbo , Richard Evan Greenberg , David Chen , Costas D. Lallas , Edouard John Trabulsi , Yu-Ning Wong , Alexander Kutikov , Jianqing Lin , Gail Duncan , Beth Adair , Charlotte Cione , Conor O'Sullivan , Deborah Kilpatrick , Eric A Ross , Stephen A. Boorjian , Robert G. Uzzo , William Kevin Kelly , Gary R. Hudes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer
Sub Track
Bladder Cancer
Clinical Trial Registration Number
NCT01031420
Citation
J Clin Oncol 30, 2012 (suppl; abstr 4526)
DOI
10.1200/jco.2012.30.15_suppl.4526
Abstract #
4526
Poster Bd #
5
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) in patients with high-grade upper-tract urothelial carcinoma.
First Author: Jean H. Hoffman-Censits
Poster
2018 Genitourinary Cancers Symposium
A phase II trial of risk-adapted treatment for muscle invasive bladder cancer after neoadjuvant accelerated MVAC.
First Author: Daniel M. Geynisman
Poster
2014 ASCO Annual Meeting
Comparative effectiveness of gemcitabine plus cisplatin (GC) versus methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC).
First Author: Matt D. Galsky
Poster
2019 ASCO Annual Meeting
Defects in DNA repair genes and long-term survival in cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer (MIBC).
First Author: Benjamin Miron